Molecular Templates (MTEM) said that on March 13, Bristol-Myers Squibb (BMY) notified the company that following a corporate portfolio prioritization process, it does not intend to continue the research collaboration it entered into with the Molecular pursuant to the BMS collaboration agreement and would be terminating the agreement in its entirety. The termination will be effective on June 13, or 90 days following the company’s receipt of Bristol-Myers Squibb’s written notice of termination. Molecular Templates plans to reduce costs related to the collaboration agreement.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTEM:
- Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
- Molecular Templates Inc Raises Funds for Clinical Studies
- Molecular Templates announces $9.5M private placement
- Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
- Two new option listings and option delistings on March 25th
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue